Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 132Pancreatic Neoplasms 36Esophageal Neoplasms 19Biliary Tract Neoplasms 18Colorectal Neoplasms 17Esophageal Squamous Cell Carcinoma 12Neoplasm Metastasis 10Cholangiocarcinoma 7Carcinoma, Non-Small-Cell Lung 7Gastrointestinal Neoplasms 6Nasopharyngeal Carcinoma 5Colonic Neoplasms 5Adenocarcinoma 5Neoplasms 4Head and Neck Neoplasms 4Advanced Pancreatic Cancer 4Advanced Gastric Cancer 4Recurrence 3Rectal Neoplasms 3Gastric Adenocarcinoma 3Advanced Solid Tumors 3Parkinson Disease 4, Autosomal Dominant Lewy Body 2NSCLC 2Locally Advanced Pancreatic Cancer 2Locally Advanced Gastric Cancer 2Gastric Cancer Peritoneal Metastases 2Gallbladder Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma, Hepatocellular 2Breast Neoplasms 2

Interventions

camrelizumab 2apatinib 2Ramucirumab 2trifluridine tipiracil drug combination 1tipiracil 1irinotecan sucrosofate 1Trifluridine 1S 1 (combination) 1Fluorouracil 1Docetaxel 1Cisplatin 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Metastatic Gastric Adenocarcinoma × S 1 (combination) × Clear all
NCT04781686 2021-05-17

Apatinib Plus Camrelizumab Combined With Docetaxel and S1 in First-line Treatment for Metastatic Gastric Cancer

Zhongnan Hospital

Phase 2 Unknown
35 enrolled
Gastrointestinal

Metastatic Gastric Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡